TY - JOUR T1 - ▼Natalizumab for multiple sclerosis? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 69 LP - 72 DO - 10.1136/dtb.2008.09.0021 VL - 46 IS - 9 A2 - , Y1 - 2008/09/01 UR - http://dtb.bmj.com/content/46/9/69.abstract N2 - Relevant BNF section: 8.2.4Around 2.5 million people worldwide have multiple sclerosis, of whom about 85,000 are in the UK.1 ▼Natalizumab (pronounced na-ta-liz-you-mab; Tysabri – Biogen Idec), the first in a new class known as selective adhesion-molecule inhibitors, is licensed in the UK as monotherapy for “highly active” relapsing/remitting multiple sclerosis.2 Here we review natalizumab and assess its place for patients with multiple sclerosis. ER -